Welcome to our dedicated page for 23andMe Holding Co. news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23andMe Holding Co. stock.
23andMe Holding Co. Class A Common Stock (NASDAQ: ME) is a leading genetics-led consumer healthcare and biopharmaceutical company. Founded in 2006, 23andMe specializes in personal genome services through DNA analysis technologies and interactive web-based tools. The company’s core service allows individuals to gain deep insights into their genetic ancestry, health predispositions, and phenotypic traits.
23andMe's mission is to personalize healthcare by supporting meaningful discoveries through genetic research. The company's primary revenue comes from its Consumer and Research Services segment, which includes the sale of direct-to-consumer personal genome services (PGS). This involves shipping DNA collection kits to users, who can then access detailed reports on their genetic makeup through 23andMe’s platform.
The company also has a Therapeutics segment that focuses on leveraging genetic data to develop new treatments. Notably, 23andMe presented positive Phase 2 safety and efficacy data from their anti-CD200R1 antibody, 23ME-00610, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Despite its groundbreaking work, 23andMe recently faced a significant data breach, affecting approximately 7 million users. Hackers specifically targeted the genetic information of Jewish and Chinese customers, selling the data on the dark web. This incident has led to a class-action lawsuit and ongoing investigations.
In research, 23andMe has also made significant strides. For example, the company conducted the world's largest study on the LRRK2 G2019S variant linked to Parkinson’s disease, with support from The Michael J. Fox Foundation. Findings from this study revealed new insights into the variant's impact and its prevalence in various populations, including unexpected hotspots in Latin Caribbean communities.
23andMe continues to expand its offerings, providing reports that calculate genetic likelihood for conditions like bipolar disorder, anxiety, and depression for its 23andMe+ Premium members. These reports are based on polygenic risk scores (PRS) developed through the company’s extensive research database.
With a strong commitment to advancing personalized healthcare and continuous innovation in genetic research, 23andMe remains a significant player in the biotechnology and consumer healthcare sectors.
On May 23, 2024, 23andMe (NASDAQ: ME) revealed that a data breach in December 2023 exposed the personal genetic information of approximately 7 million users. Hackers specifically targeted Jewish and Chinese customers, compiling and selling their data on the dark web. A class action lawsuit claims 23andMe concealed these details when notifying affected users. The leaked data included genetic heritage, names, addresses, and health information. The breach poses significant safety risks, especially from governments like China's. 23andMe has not yet directly informed all compromised customers about the leak.
On May 22, 2024, 23andMe disclosed a major data breach that occurred in December 2023, affecting approximately 7 million users. Hackers targeted Jewish and Chinese users' personal genetic information, selling it on the dark web. Despite knowing the specifics, 23andMe did not inform the affected users of the ethnic targeting or the extent of the breach. A class action lawsuit has been filed, claiming the breach has endangered the safety of those listed, especially from governmental tracking. The lawsuit also mentions that the company tried to blame users for reusing login credentials.
23andMe (NASDAQ:ME) experienced a data breach in December 2023, affecting 7 million users. Hackers specifically targeted Jewish and Chinese customers, leaking personal genetic information including names and addresses, which was then sold on the dark web. Despite knowing the specific targeting, 23andMe did not inform the affected customers in their December notification. A class action lawsuit has been filed, accusing the company of concealing the extent of the breach and the specific targeting of Jewish and Chinese users. The leaked data has raised significant safety concerns, especially for Chinese customers due to potential government tracking.
On May 17, 2024, 23andMe (NASDAQ:ME) disclosed a data breach from December 2023 that affected approximately 7 million users. Hackers specifically targeted Jewish and Chinese customers, selling their personal genetic information on the dark web. A class action lawsuit alleges that 23andMe concealed these details when informing customers about the breach. The targeted data included genetic heritage, names, and addresses. The breach has raised safety concerns, particularly for Chinese customers worried about government surveillance. The lawsuit claims that 23andMe has yet to notify affected users about the specific targeting and the sale of their data online.
On May 16, 2024, 23andMe (NASDAQ:ME) revealed that hackers breached their systems in December 2023, affecting 7 million users. The hack specifically targeted Jewish and Chinese customers, compiling their personal genetic data, which was sold on the dark web. A class action lawsuit alleges that 23andMe concealed these details from those affected. The hacker leaked lists of over 1 million Jewish and 350,000 Chinese customers, generating significant interest on the dark web. 23andMe initially attributed the breach to recycled login credentials and delayed the announcement until December without mentioning the specific targeting or data sale. Law firm Levi & Korsinsky is investigating potential compensation for affected users.
23andMe (NASDAQ: ME) experienced a major data breach in December 2023, affecting 7 million users. Hackers targeted Jewish and Chinese customers, extracting and selling their genetic information on the dark web. The breach was disclosed in December 2023, but the specific targeting was concealed until a recent class action complaint. Hackers leaked lists of over 1 million Jewish and 350,000 Chinese customers, raising serious safety concerns. The company has yet to inform all affected users. Legal action is underway, and affected individuals in certain states are urged to seek compensation.
Lemonaid Health, a subsidiary of 23andMe Holding Co. (Nasdaq: ME), announces its collaboration with Petros Pharmaceuticals (Nasdaq: PTPI) to offer STENDRA® (avanafil), a prescription ED medication, through its telehealth platform. This medication acts within 15 minutes and will be available at improved pricing. With an estimated one in 10 men experiencing ED, this initiative aims to enhance medication accessibility and affordability. Lemonaid Health, which has treated over 200,000 ED patients, provides medication delivery across the U.S. from a 50-state licensed pharmacy. The collaboration aims to offer patients better access to brand-name medications.
23andMe (NASDAQ:ME) faced a data breach affecting 7 million users, with hackers targeting Jewish and Chinese customers and selling their genetic information on the dark web. The breach compromised personal data, posing potential risks to affected customers. 23andMe failed to disclose the specific targeting of these groups, leading to legal action and concerns over customer safety.
23andMe Holding Co. (Nasdaq: ME) will announce its financial results for Q4 and FY2024 on May 23, 2024. The company aims to discuss its business progress during a webcast at 4:30 p.m. Eastern Time on the same day. Shareholders can participate in the Q&A session by submitting questions in advance. The webcast link will be available at https://investors.23andme.com/news-events/events-presentations.
23andMe (NASDAQ:ME) experienced a data breach in December 2023, impacting 7 million users. The hackers specifically targeted Jewish and Chinese customers, selling their genetic information on the dark web. The breach poses a significant threat to affected customers, with 23andMe failing to disclose the extent of the breach and the specific targeting of Jewish and Chinese users. Levi & Korsinsky, LLP is investigating potential compensation for affected individuals.
FAQ
What is the current stock price of 23andMe Holding Co. (ME)?
What is the market cap of 23andMe Holding Co. (ME)?
What does 23andMe specialize in?
How does 23andMe generate its revenue?
What recent research has 23andMe conducted?
What was the recent data breach involving 23andMe?
What are 23andMe's key offerings for 23andMe+ Premium members?
Who are 23andMe's main partners in research?
What is 23andMe's vision?
What is 23ME-00610?
How does 23andMe protect user data?
How can customers participate in 23andMe's research?
